LAURUSLABS Q1 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,570 Cr
verified against source
Revenue YoY
31%
reported change
EBITDA
₹389 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Laurus Labs delivered a strong Q1 FY26 with revenue of INR 1,570 crore (+31% YoY), driven by robust CDMO momentum and generics volume expansion. EBITDA margin expanded 1,050bps to 25%, reflecting better operating leverage and favorable product mix, with gross margins at ~59%. PAT grew 13% YoY to INR 163 crore. CDMO contributed over 30% of revenue with strong mid-to-late stage molecule deliveries, while the 110-project pipeline (90 human health, 20 animal health/crop science) provides multi-year visibility. The company announced three major capacity expansions—microbial fermentation greenfield at Vizag (400kL Phase 1), gene therapy/ADC GMP facility in Hyderabad, and finished formulation facility under Karka JV—backed by a INR 5,000 crore CapEx plan over 4-5 years. Management targets 55-60% gross margins going forward as CDMO mix increases toward 50% potential contribution. Key risks include ARV pricing pressure from Global Fund tender dynamics and inherent quarterly FDF revenue lumpiness.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects gross margins to sustain in the 55-60% range going forward as CDMO contribution increases, up from the previous ~55% guidance.
- Capacity expansion for non-ARV formulations is underway with qualification expected by end of FY26, enabling growth acceleration from Q4 onwards.
- CDMO segment expected to achieve INR 2,500 crore plus range for FY26, with good visibility on molecules, volumes, customers and pricing.
- Company announced INR 5,000 crore cumulative CapEx investment over 4-5 years, funded primarily through internal accruals, maintaining net debt below 50% of revenue.
Risks flagged
- Significant price drop expected in ARVs; management maintained FY26 guidance with cushion as incremental volumes may compensate for price erosion. Global Fund tender cycle ending December 2025 adds uncertainty.
- Finished dosage form sales fluctuate based on regulatory approvals from various countries, logistics, and fee-for-service shipment timing—revenue recognition timing creates quarter-to-quarter variability.
- Management explicitly admitted redirecting R&D resources from generic API development to CDMO projects, suppressing non-ARV API growth for the next few quarters until R&D expansion is complete.
- Larbio division faced customer-specific scale-up challenges causing flat Q1 performance. Though bottleneck is resolved, revenue ramp-up timing remains uncertain with full-year targets dependent on successful qualification.
Key quotes
- As we grow our CDMO business, as we see today we haven't achieved operational efficiency, still a lot of unutilized capacities. As we grow our revenues, we are not going to grow our R&D and quality staff proportionately.
- We are going to invest INR 5,000 crores in the next four to five years. Cash flows, internal cash flows will be sufficient to take care of it. We don't make our net debt more than 50% of our revenue at any point of time.
- The CDMO contributes over 30% of our revenue. We expect this will continue to grow. In the near to medium term, we expect it has a potential to touch 50%.
- There is no challenge. It's only delay. The project now the bottleneck was resolved, things are back to normal. And we don't see when we look at the entire year, we don't see any big challenge achieving what numbers we thought at the beginning of the year.
Research modules